SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluxion Biosciences, Inc. announced today that it has launched an Early Access Program for its IsoFlux Rare Cell Access System. The program will enable scientists to incorporate circulating tumor cells (CTC) and other rare cell assays into their research prior to the IsoFlux commercial product release.
